ELI LILLY AND COMPANY Research and Development Asset Acquired Other than Through Business Combination, Written-off
ELI LILLY AND COMPANY (LLY) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $2.78 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-08-05
- ELI LILLY AND COMPANY research and development asset acquired other than through business combination, written-off for the quarter ending 2026-06-30 was $2.78B, a 1702.60% increase year-over-year.
- ELI LILLY AND COMPANY research and development asset acquired other than through business combination, written-off for the quarter ending 2026-03-31 was $584.00M, a 62.85% decline year-over-year.
- ELI LILLY AND COMPANY research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $528.80M, a 180.08% increase year-over-year.
- ELI LILLY AND COMPANY research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-30 was $655.70M, a 76.80% decline year-over-year.
- ELI LILLY AND COMPANY research and development asset acquired other than through business combination, written-off for fiscal 2025 was $2.91B, a 11.28% decline from fiscal 2024.
- ELI LILLY AND COMPANY research and development asset acquired other than through business combination, written-off for fiscal 2024 was $3.28B, a 13.68% decline from fiscal 2023.
- ELI LILLY AND COMPANY research and development asset acquired other than through business combination, written-off for fiscal 2023 was $3.80B, a 318.27% increase from fiscal 2022.
- ELI LILLY AND COMPANY research and development asset acquired other than through business combination, written-off for fiscal 2022 was $908.50M, a 6.35% decline from fiscal 2021.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.78B 10-Q · filed 2026-08-05 | $3.36B 10-Q · filed 2026-08-05 | $3.89B derived: sum of 3 quarters · filed 2026-08-05 | $4.54B derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $584.00M 10-Q · filed 2026-04-30 | $1.11B derived: sum of 2 quarters · filed 2026-04-30 | $1.77B derived: sum of 3 quarters · filed 2026-04-30 | $1.92B derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $528.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.18B derived: sum of 2 quarters · filed 2026-02-12 | $1.34B derived: sum of 3 quarters · filed 2026-08-05 | $2.91B 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $655.70M 10-Q · filed 2025-10-30 | $809.70M derived: sum of 2 quarters · filed 2026-08-05 | $2.38B 10-Q · filed 2025-10-30 | $2.57B derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $154.00M 10-Q · filed 2026-08-05 | $153.80M 10-Q · filed 2025-08-07 | $1.73B 10-Q · filed 2026-08-05 | $1.73B 10-Q · filed 2025-08-07 | $1.91B derived: sum of 3 quarters · filed 2026-08-05 | $4.74B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $1.57B 10-Q · filed 2026-04-30 | $1.57B 10-Q · filed 2025-05-01 | $1.76B derived: sum of 2 quarters · filed 2026-04-30 | $4.59B derived: sum of 3 quarters · filed 2026-04-30 | $4.74B derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-12-31 | $188.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $3.02B derived: sum of 2 quarters · filed 2026-02-12 | $3.17B derived: sum of 3 quarters · filed 2026-02-12 | $3.28B 10-K · filed 2026-02-12 | $3.28B 10-K · filed 2025-02-19 | ||
| 2024-09-30 | $2.83B 10-Q · filed 2025-10-30 | $2.98B derived: sum of 2 quarters · filed 2025-10-30 | $3.09B 10-Q · filed 2025-10-30 | $3.71B derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2024-06-30 | $154.30M 10-Q · filed 2025-08-07 | $264.80M 10-Q · filed 2025-08-07 | $887.60M derived: sum of 3 quarters · filed 2026-02-12 | $3.86B derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2024-03-31 | $110.50M 10-Q · filed 2025-05-01 | $733.30M derived: sum of 2 quarters · filed 2026-02-12 | $3.71B derived: sum of 3 quarters · filed 2026-02-12 | $3.81B derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2023-12-31 | $622.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $3.60B derived: sum of 2 quarters · filed 2026-02-12 | $3.69B derived: sum of 3 quarters · filed 2026-02-12 | $3.80B 10-K · filed 2026-02-12 | $3.80B 10-K · filed 2024-02-21 | ||
| 2023-09-30 | $2.98B 10-Q · filed 2024-10-30 | $3.07B derived: sum of 2 quarters · filed 2024-10-30 | $3.18B 10-Q · filed 2024-10-30 | $3.42B derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-06-30 | $97.10M 10-Q · filed 2024-08-08 | $202.10M 10-Q · filed 2024-08-08 | $442.20M derived: sum of 3 quarters · filed 2025-02-19 | $504.60M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-03-31 | $105.00M 10-Q · filed 2024-04-30 | $345.10M derived: sum of 2 quarters · filed 2025-02-19 | $407.50M derived: sum of 3 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | $240.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $302.50M derived: sum of 2 quarters · filed 2025-02-19 | $908.50M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | $62.40M 10-Q · filed 2023-11-02 | $668.40M 10-Q · filed 2023-11-02 | |||||
| 2021-12-31 | $970.10M 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |